Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Rein Therapeutics (RNTX) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $25.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 41.84% to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, up 41.84% year-over-year, with the annual reading at $25.4 million for FY2025, 41.84% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $25.4 million at Rein Therapeutics, up from $24.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $90.5 million in Q3 2021, with the low at $4.4 million in Q4 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $19.5 million, with a median of $8.3 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 94.98% in 2022, then soared 290.09% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $4.4 million in 2021, then rose by 2.23% to $4.5 million in 2022, then rose by 1.31% to $4.6 million in 2023, then skyrocketed by 290.09% to $17.9 million in 2024, then skyrocketed by 41.84% to $25.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $25.4 million, $24.2 million, and $23.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.